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Post-marketing surveillance activities (namely pharmacovigilance) are crucial to favor the
early detection of unexpected adverse events (AEs) and/or serious adverse reactions
(SAEs). Indeed, spontaneous reporting of AEs has been demonstrated to underestimate
the number of events in different clinical settings. Aim of the present study is to report the
preliminary data of a Regional (Calabria, Italy) Pharmacovigilance Program (CBPP) aimed
at improving AEs’ reporting associated with biologics use in rheumatology.
Materials and methods
We developed a simple, cost-effective pharmacovigilance program based on regular training
sessions for physicians (stimulated reporting), periodical phone calls by a clinical pharmacol-
ogist aimed at identifying new events and stimulating self-awareness and encouraging
reporting to the physician during the subsequent follow-up visit for minor AEs. To test this
approach, all consecutive patients undergoing treatment with one biologic agent at eight
rheumatology centers during a two-years period were invited to participate. Collected AEs
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were compared to the number of AEs spontaneously reported for the same molecules in the
same centers before starting the protocol.
Results
During the study period, 399 patients (245 females; mean age: 58 ± 11 years) were started
on treatment with biologics for active RA (n = 211, 52.9%), PsA (n = 119, 29.8%) or AS (n =
69, 17.3%) at eight rheumatology centers. A total of 125 AEs (31.3%) and 9 SAEs (2.3%)
were reported during the two-years study period. In the control cohort (comprising 368 con-
secutive patients started on treatment with bDMARDs during a two-years period before
CBPP study) only 42 (11.4%) AEs and no SAEs were reported (p < 0.0001). The most com-
mon AEs were injection site reactions and skin disorders.
Conclusions
In conclusion, our study provides further evidence of a critical role of active pharmacovigi-
lance in detection, reporting and analysis of AEs in rheumatology.
Introduction
Inflammatory arthritides is an umbrella term comprising a heterogeneous group of chronic
immune-mediated diseases affecting the joints and tendons such as rheumatoid arthritis (RA),
psoriatic arthritis (PsA), and ankylosing spondylitis (AS) and affecting *5% of population
worldwide [1]. Patients with inflammatory arthritis experience recurring or chronic episodes
of joints/tendons inflammation, leading ultimately to subversion of the normal anatomy and,
consequently, a variable degree of functional disability [2].
Treatment options were limited for a long time to nonsteroidal anti-inflammatory drugs
(NSAIDs), corticosteroids (CCs) and conventional synthetic disease-modifying anti-rheumatic
drugs (csDMARDs), in particular methotrexate (MTX) [3–5].
In the last two decades, clinical practice has been revolutionized following the development
and marketing of several new biologic DMARDs (bDMARDs) resulting in a dramatic
improvement in the management of refractory patients [3]. These molecules can selectively
target soluble mediators involved in the development and maintenance of inflammatory pro-
cesses such as tumor necrosis factor-alpha (TNF-α) [6], interleukin-1 (IL-1) [7] and -6 (IL-6)
[8] or surface molecules involved in T-cells activation (such as the CTLA-4—CD80/86 path-
way) [9] or B cell survival signals (such surface CD20) [10]. At present, five TNF-α antagonists
(TNFi) (adalimumab—ADA; etanercept—ETN; certolizumab pegol—CZP and golimumab—
GOL, for subcutaneous administration; infliximab—IFX for intravenous infusion), one IL-17
inhibitor (secukinumab—SEC), one IL-12/23 inhibitor (ustekinumab—UST), one IL-6 recep-
tor antagonist (tocilizumab—TCZ), one IL-1 inhibitor (anakinra—ANA), one T-cell co-stimu-
lation inhibitor (abatacept—ABT), and one B-cell depleting agent (rituximab—RTX) are
approved by European Medicines Agency (EMA) for treatment of patients with inflammatory
arthritis. In details, all TNFis are approved for either RA, PsA or AS; SEC is approved for PsA
and AS; ABT, TCZ and ANA are approved for RA only while, UST is approved for PsA.
All bDMARDs, due to their higher costs, are currently recommended for the treatment of
patients with active disease and insufficient response or intolerance to csDMARDs [11,12],
with the exception of individuals with definite clinical characteristics, such as those with axial-
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predominant spondyloarthritis (axSpA) [13], in which bDMARDs are recommended as a
first-line therapy following the unsuccess of NSAIDs or topical steroid injections. Besides their
well-established role in ameliorating control of disease activity, bDMARDs have been associ-
ated with safety concerns. Infections (including tuberculosis and opportunistic) [14,15], skin
cancers [16], demyelinating leukoencephalopathy [17] and hepatitis B reactivation [18] have
been reported during therapy with bDMARDs in clinical trials and real-life studies.
In this context, post-marketing surveillance activities (namely pharmacovigilance) are cru-
cial to favor the early detection of unexpected adverse events (AEs) and/or serious adverse
reactions (SAEs). Indeed, spontaneous reporting of AEs has been demonstrated to underesti-
mate their number [19,20] in different clinical settings. At odds, active pharmacovigilance
activities may actually improve detection and reporting of AEs [21] and represent a powerful
tool to better define the safety profile of marketed molecules and to establish risk factors or
frail patient phenotypes.
Aim of the present study is to report the preliminary data of a Regional (Calabria, Italy)
Pharmacovigilance Program aimed at improving reporting of AEs associated with biologics
use in rheumatology.
Materials and methods
Calabria Biologics Pharmacovigilance Program
The Calabria Biologics Pharmacovigilance Program (CBPP) is a multicenter pharmacovigi-
lance study aimed at improving the continuous monitoring of safety of bDMARDs treatment
in clinical practice. The purpose of the program is to implement a simple active AEs reporting
system in all tertiary rheumatology clinics dealing with bDMARDs distributed across Calabria
Region (Italy) in different fields of medicine including rheumatology, gastroenterology and
dermatology. Since its starting in 2016, the program develops through regular training sessions
for physicians during dedicated one-day pharmacovigilance courses (at least two courses/year)
in order to improve awareness/compliance and therefore boost the reporting (stimulated
reporting) attitude during scheduled follow-up visits. The physician dealing with an AE is pro-
vided with a direct interface with the Clinical Pharmacology and Pharmacovigilance Unit at
University of Catanzaro “Magna Graecia” by either email, program website and dedicated
phone number. Structured data are collected for each AE, including Medical Dictionary for
Regulatory Activities (MedDRA) classification of the event, duration, severity and outcome.
Furthermore, during the whole follow-up period, patients received periodical phone calls by a
clinical pharmacologist (approximately one every three months) aimed at identifying new
events, stimulating self-awareness and encouraging reporting to the physician during the sub-
sequent follow-up visit for minor AEs. The global costs associated with the program for the
rheumatology therapeutic area are related to the recruiting of one dedicated clinical pharma-
cologist (EUR 28.000/year) and the expenses for the organization of training courses and meet-
ings (approximately EUR 10.000/year).
The study protocol was approved by the local Ethics Committee (Comitato Etico Regionale
Calabria, Italy), protocol number 278/2015. Informed consent was obtained from all patients
at the time of enrollment which were informed that medical records will be anonymously uti-
lized for this study. All procedures were performed in accordance with the 1964 Declaration of
Helsinki and its later amendments.
Patients
In this preliminary report, we provide the data obtained during the first two years of the CBPP
—Rheumatology therapeutic area. To this purpose, all consecutive patients undergoing
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treatment with one bDMARD at eight rheumatology centers (Rheumatology Outpatient
Clinic, Azienda Ospedaliera “Pugliese-Ciaccio”, Catanzaro, Italy; Rheumatology Unit, Grande
Ospedale Metropolitano “Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy; Rheumatology
Outpatient Clinic, Azienda Ospedaliera “Mater Domini”, Catanzaro, Italy; Rheumatology
Outpatient Clinic, Azienda Ospedaliera Provinciale Crotone, Crotone, Italy; Rheumatology
Unit, Azienda Ospedaliera “SS Annunziata”, Cosenza, Italy; Rheumatology Outpatient Clinic
Azienda Ospedaliera Cosenza, Cosenza Italy; Rheumatology Unit, Ospedale Castrovillari, Cas-
trovillari, Italy; Rheumatology Outpatient Clinic, Azienda Sanitaria Provinciale Vibo Valentia,
Vibo Valentia, Italy) between January 1, 2016 and December 31, 2017 and satisfying prede-
fined criteria were included. These centers account for > 90% of total bDMARDs prescription
for the rheumatology area in Calabria Region.
Patients were included in the protocol if met all the following inclusion criteria:
1. age� 18 years;
2. past diagnosis of RA, AS or PsA;
3. starting treatment with one bDMARD.
The date of the first bDMARD prescription during the study period represented the “index
date” for each individual patient. From the index date onward, the patient was started on a
hybrid reporting system, characterized by “stimulated” reporting of AEs by the managing phy-
sician during each outpatient visit and intermediate phone calls to the patients by a clinical
pharmacologist as described above.
For each patient, the following information were collected: demographic and clinical
characteristics including age, sex, diagnosis (RA, PsA or AS), disease duration, current
or prior use of antirheumatic medications including csDMARDs, corticosteroids and
bDMARDs, comorbidities, discontinuation or switch/swap to another molecule with reason,
and adverse events. Patients were considered to have discontinued treatment if they did not
take that specific agent after the recommended dosing interval had passed, regardless of
whether they subsequently switched to another biological agent; conversely, patients were
defined “persistent” if they were still on treatment with the same drug during the last 3
months of the follow-up period. The reasons for treatment discontinuation were classified as
inefficacy or AEs. Furthermore, patients were classified as switchers if they were initiated on
treatment with a bDMARD other than the one reported on the index date during the study
follow-up period.
Furthermore, AEs were collected through active reporting and phone calls. For each AE,
the investigator (clinician or pharmacologist) recorded a detailed description of the detected
AE, including the onset date, severity, time-course, duration and outcome. All AEs were coded
according to the MedDRA dictionary version 20.0. SAEs were defined as events that were fatal
or life threatening and resulted in a persistent or major disability or incapacity, required pro-
longed inpatient hospitalization, or led to a congenital anomaly or birth defect. For compari-
son, the number of AEs spontaneously reported for the same molecules in the same centers
before starting the protocol (January 1, 2014 to December 31, 2015) were used.
Statistical analysis
Demographic and baseline characteristics were summarized using descriptive statistics. Contin-
uous data are presented as mean ± standard deviation (SD) or median (25–75 percentile) as
appropriate, while ordinal data are expressed as number (percentage). The Fisher’s exact test for
qualitative variables was used to compare the number of ADRs before and after implementing
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the CBPP protocol. The significance level was set at a p value< 0.05. SPSS 22.0 software (Chi-
cago, IL) was used for statistical analysis.
Results
General characteristics of the study population
General characteristics of the CBPP study population are summarized in Table 1.
During the study period, 399 patients (245 females; mean age: 58 ± 11 years) were started
on treatment with bDMARDs for active RA (n = 211, 52.9%), PsA (n = 119, 29.8%) or AS
(n = 69, 17.3%) at eight rheumatology centers distributed across Calabria Region (Southern
Italy). Overall, 49 (12.3%) patients received infliximab (IFX), 92 (23.1%) etanercept (ETN), 85
(21.3%) adalimumab (ADA), 41 (10.3%) golimumab (GOL), 14 (3.5%) certolizumab pegol
(CZP), 51 (12.8%) abatacept (ABT), 38 (9.5%) tocilizumab (TCZ), 10 (2.5%) ustekinumab
(UST) and 19 (4.8%) secukinumab (SEC); furthermore, 226 (56.6%) of them received






Female sex, n (%) 237 (64.4) 245 (61.4) 0.41
Age, years 56 ± 10 58 ± 11 0.02
Follow-up, months 11 ± 4 20 ± 2 <0.0001
Diagnosis
RA, n (%) 194 (52.7) 211 (52.9) 1.00
PsA, n (%) 123 (33.4) 119 (29.8) 0.31
AS, n (%) 51 (13.8) 69 (17.3) 0.19
Concurrent treatments
MTX, n (%) 97 (26.3) 137 (34.3) 0.01
LEF, n (%) 2 (0.5) 7 (1.8) 0.18
HCQ, n (%) 0 9 (2.3) 0.004
CyA, n (%) 0 6 (1.5) 0.03
CCS, n (%) 23 (6.2) 38 (9.5) 0.11
NSAIDs, n (%) 12 (3.3) 29 (7.2) 0.01
bDMARDs prescribed
IFX, n (%) 58 (15.8) 49 (12.3) 0.18
ETN, n (%) 89 (24.2) 92 (23.1) 0.73
ADA, n (%) 78 (21.2) 85 (21.3) 1.00
GOL, n (%) 50 (13.6) 41 (10.3) 0.18
CZP, n (%) 5 (1.3) 14 (3.5) 0.06
ABT, n (%) 53 (14.4) 51 (12.8) 0.53
TCZ, n (%) 35 (9.51) 38 (9.5) 1.00
UST, n (%) 0 10 (2.5) 0.002
SEC, n (%) 0 19 (4.8) <0.0001
Adverse events
AEs, n (%) 42 (11.4) 125 (31.3) <0.0001
SAEs, n (%) 0 9 (2.3) 0.004
CBPP, Calabria Biologics Pharmacovigilance Program; MTX, methotrexate; LEF, leflunomide; HCQ,
hydroxychloroquine; CyA, cyclosporin A; CCS, corticosteroids; NSAIDs, Nonsteroidal anti-inflammatory drugs;
IFX, infliximab; ETN, etanercept; ADA, adalimumab; GOL, golimumab; CZP, certolizumab pegol; ABT, abatacept;
TCZ, tocilizumab; UST, ustekinumab; SEC, secukinumab; AEs, adverse events; SAEs, serious adverse events.
https://doi.org/10.1371/journal.pone.0205134.t001
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concurrent treatment with either one or more csDMARDs, NSAIDs or corticosteroids. None
received rituximab (RTX). At the time of treatment initiation, the majority (n = 287, 71.9%) of
patients were bDMARDs-naïve; the remaining switched/swapped from one or more previous
bDMARDs (number of previous bDMARDs range: 0–3). Data reported refer to switches dur-
ing study inclusion (see Table 2 for details about switches).
Prevalence of AEs before and after starting the CBPP
As detailed in methods, the CBPP pharmacovigilance study protocol was started in January
2016. Accordingly, all patients undergoing treatment with one bDMARD at recruiting centers
during the subsequent 24 months were recruited. Following the implementation of the CBPP,
125 AEs (31.3%) and 9 SAEs (2.3%) were reported during the two-years study period. In the
control cohort (comprising 368 consecutive patients started on treatment with bDMARDs
during a two-years period before CBPP study) only 42 (11.4%) AEs and no SAEs were
reported, thus resulting in a statistically significant difference in favor of CBPP protocol
(p< 0.0001, Fig 1).
In the CBPP cohort, AEs were most frequently reported with secukinumab (78.9%), goli-
mumab (48.8%), abatacept (41.2%), certolizumab pegol (35.7%), tocilizumab (31.6%), usteki-
numab (30%), etanercept (25%), adalimumab (18.8%) and infliximab (14.3%) (Fig 2).
The most common adverse events were injection site reactions and skin disorders. A
detailed list of AEs classified according to the MedDRA dictionary is provided in Tables 3
and 4. A total of 9 SAEs were reported during the CBPP study period: two cases of severe
uveitis leading to permanent visual loss (infliximab and golimumab), three cases thrombocy-
topenia leading to major bleeding (etanercept, abatacept and secukinumab), two cases of
severe hemorrhage without thrombocytopenia (abatacept), one case of progressive multifo-
cal leukoencephalopathy (adalimumab) and one case of new-onset multiple sclerosis
(golimumab).
Discussion
The therapeutic approach to inflammatory arthritides has been radically changed by the
development and marketing of several bDMARDs. These molecules, differently from
csDMARDs, can selectively target key pathophysiological mechanisms involved in inflam-
matory arthritis immunopathogenesis and, despite their significantly higher cost, represent
Table 2. Details on switches between bDMARDs.
Switch to
Switch from IFX ETN ADA GOL CZP ABT TCZ UST SEC
IFX 11 5(1) 8 \ 2(3) 1 1 1
ETN 2 13(1) 8(1) 1 5 2 2 5
ADA 1 12(2) 9(1) 5 7(3) 3 3 3(1)
GOL 2 3 2(1) \ 1 1(2) 1(1) 1
CZP \ \ \ \ 1 1 \ 1
ABA 1 \ 1(1) 1(1) 1 3 \ \
TOC \ 2 \ 1 \ 3 \ \
UST \ \ 1 \ \ \ \ 4
SEC \ \ \ \ \ \ \ \
Switches related to inefficacy (switches related to AEs); IFX, infliximab; ETN, etanercept; ADA, adalimumab; GOL, golimumab; CZP, certolizumab pegol; ABT,
abatacept; TCZ, tocilizumab; UST, ustekinumab; SEC, secukinumab.
https://doi.org/10.1371/journal.pone.0205134.t002
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Fig 1. Prevalence of adverse events (AEs) and serious adverse events (SAEs) before and after CBPP protocol implementation.
https://doi.org/10.1371/journal.pone.0205134.g001
Fig 2. Prevalence of adverse events (AEs) before and after CBPP protocol implementation for individual bDMARDs.
https://doi.org/10.1371/journal.pone.0205134.g002
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nowadays an essential bullet in the rheumatology therapeutic armamentarium. Meta-analy-
ses of clinical trials robustly demonstrated their efficacy and the overall favorable safety pro-
file [22]. However, when dealing with molecules potentially affecting key physiological
functions such as protective immune homeostasis, safety data produced during clinical trials
may be insufficient to unravel the real impact of the treatment in clinical setting. Indeed,
despite the strong methodology, clinical trials have some limitations in detecting rare or
uncommon adverse events, mainly related to the restrictive inclusion criteria, the narrowly-
coded disease phenotype (i.e. classification criteria) and the relatively short follow-up period.
Furthermore, patients in clinical trials undergo a tight follow-up protocol allowing identifi-
cation and prevention of some AEs, which is often very different from the follow-up policy
used in clinical practice.
Table 3. MedDRA-compliant description of adverse events (AEs) after CBPP implementation.
IFX ETN ADA GOL CZP ABT TCZ UST SEC Total
SOC—General disorders and administration site conditions 1 15 8 14 4 14 6 1 7 70
PT2—Administration site reaction 15 8 14 4 13 6 1 7 68
PT3—Hyperthermia 1 1 2
SOC—Vascular disorders 2 2
PT—Haemorrhage 2� 2
SOC—Skin and subcutaneous tissue disorders 1 3 2 3 1 2 1 3 16
PT1—Rash 1 3 1 3 1 2 1 3 15
PT2—Nail disorder 1 1
SOC—Ear and labyrinth disorders 2 2
PT—Tinnitus 2 2
SOC—Nervous system disorders 2 1 2 1 1 7
PT—Progressive multifocal leukoencephalopathy 1� 1
PT2—Headache 2 1 1 1 5
PT3—Demyelination 1� 1
SOC—Infections and infestations 1 1 2 2 6
PT—Pneumonia viral 2 2
PT2—Herpes simplex 1 1 2 4
SOC—Respiratory, thoracic and mediastinal disorders 1 1 1 2 5
PT—Benign respiratory tract neoplasm 1 1
PT2—Dyspnoea 1 1 2 4
SOC—Investigations 1 2 1 1 1 6
PT—Red blood cell sedimentation rate abnormal 1 1 2
PT2—White blood cell count abnormal 1 1 1 1 4
SOC—Blood and lymphatic system disorders 1 1 1 3
PT—Thrombocytopenia 1� 1� 1� 3
SOC—Gastrointestinal disorders 1 2 1 4 3 3 14
PT—Nausea 1 2 1 2 2 3 11
PT2—Anal fistula 1 1
PT3—Vomiting 2 2
SOC—Immune system disorders 1 1 2
PT—Uveitis 1� 1� 2
� Classified as serious adverse event (SAE)
IFX, infliximab; ETN, etanercept; ADA, adalimumab; GOL, golimumab; CZP, certolizumab pegol; ABT, abatacept; TCZ, tocilizumab; UST, ustekinumab; SEC,
secukinumab.
https://doi.org/10.1371/journal.pone.0205134.t003
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According to the World Health Organization (WHO) definition, pharmacovigilance is
“the science and activities relating to the detection, assessment, understanding and prevention
of adverse effects or any other drug-related problem”. Aim of pharmacovigilance is therefore
to implement strategies to improve the early detection of AEs, to identify risk factors and
special patient’s populations (i.e. elderly) and finally to produce strategies to minimize the
risk thus preventing patients from being affected unnecessarily. Spontaneous reporting of
suspected AEs represents the cornerstone of pharmacovigilance, allowing to rapidly detect
potential warning signals related to medication use through the early detection of new AEs.
Furthermore, the involvement of a wide range of healthcare professionals (physician, nurse,
clinical pharmacist) confers to this epidemiological approach a role of “alarm” in the identifi-
cation of events with very low frequency [23]. However, although post-marketing surveil-
lance plays an essential role in patient safety, it is often biased by a significant degree of
underreporting [24] with an overall estimate of only 6–10% of all AEs reported. This phe-
nomenon is a major limitation of spontaneous reporting, considering that, AEs have a great
impact on public health and represent a significant economic burden on both healthcare sys-
tems and society [25].
Table 4. MedDRA-compliant description of adverse events (AEs) before CBPP implementation.
IFX ETN ADA GOL CZP ABT TCZ UST SEC Total
SOC—General disorders and administration site conditions 2 5 4 1 1 13
PT2—Administration site reaction 3 2 4
PT3—Hyperthermia 1 1 2
PT4—Hyperhidrosis 1 1
PT5—Asthenia 1 2 1 1 5
SOC—Nervous system disorders 2 1 1 4
PT1—Headache 2 2
PT2—Demyelination 1 1
PT3—Confusional state 1 1
SOC—Skin and subcutaneous tissue disorders 4 1 3 1 9
PT1—Rash 4 1 3 1 9
SOC—Eye disorders 2 2
PT—Visual impairment 2 2
SOC—Ear and labyrinth disorders 1 2 3
PT1—Hypoacusis 1 1
PT2—Vertigo 1 1 2
SOC—Gastrointestinal disorders 4 1 5
PT1—Nausea 2 1 3
PT2—Vomiting 2 2
SOC—Investigations 1 1 2
PT1—Hepatitis C antibody positive 1 1
PT2—Transaminases increased 1 1
SOC—Respiratory, thoracic and mediastinal disorders 4 1 5
PT2—Dyspnoea 1 1
PT3—Throat tightness 3 1 4
SOC—Blood and lymphatic system disorders 1 1
PT—Thrombocytopenia 1 1
IFX, infliximab; ETN, etanercept; ADA, adalimumab; GOL, golimumab; CZP, certolizumab pegol; ABT, abatacept; TCZ, tocilizumab; UST, ustekinumab; SEC,
secukinumab.
https://doi.org/10.1371/journal.pone.0205134.t004
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Based on these alarming data, on July 21, 2012, a new EU pharmacovigilance legislation
came into force in order to strengthen and rationalize the EU pharmacovigilance system, mini-
mize AEs and enhance drugs safety [26].
In the present study, we reported the performance of a simple, cost-effective active pharma-
covigilance program in increasing the number of reported ADRs associated with bDMARDs
therapy in rheumatology. Our study, by means of implementing a hybrid reporting system
(stimulated spontaneous reporting and phone calls) favored a significant increase in both the
number and the quality of AEs reported, in sharp contrast with the reporting behavior before
protocol implementation, thus contributing to reduce the under-reporting phenomenon and
providing insightful information on AEs in real life clinical practice. Following the CBPP
study implementation, indeed, the number of AEs in the study cohort increased significantly
(+274%) although still not reaching the figures observed in the majority of rheumatology regis-
tries such as the Italian GISEA registry [27] (AEs: 57%) or the Spanish BIOBADASER [28]
(80.7%).
The crucial role of active pharmacovigilance in stimulating AEs reporting has been already
demonstrated in several Italian studies including pediatric [29] and elderly patients [30].
Recently, an observational study (BIO-Cam) investigated the occurrence of AEs in naïve
patients receiving biologic drugs in several settings (including rheumatology), supporting our
findings that pharmacovigilance programs may represent a winning strategy to improve the
knowledge of safety profile of these new drugs [31]. Similarly, the project “FarmaREL” pro-
duced a significant increase of spontaneous AEs reporting among hematology specialists [32].
Finally, an observational study conducted by an Italian National Cancer Institute confirmed
the essential role of pro-active pharmacovigilance in increasing spontaneous reporting of AEs
associated with anticancer targeted-therapies [33].
Conclusions
Our study, although biased by some limitations including a relatively small sample size and the
consequent lack of power for estimates of AEs for individual molecules, provides further evi-
dence of a critical role of active pharmacovigilance in detection, reporting and analysis of AEs
in rheumatology.
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